The Liver Meeting 2020-Hepatology Associates SIG Interdisciplinary Approach to Managing Metabolic Syndrome in NAFLD/NASH Patients

Hepatology Associates SIG Interdisciplinary Approach to Managing Metabolic Syndrome in NAFLD/NASH Patients

Video Transcription

Video Summary

The Liver Meeting 2020 sessions by Hepatology Associates SIG focused on managing metabolic syndrome in NAFLD NASH patients, discussing diagnosing and treating NAFLD, NASH, and new therapies. Topics included assessing cardiovascular risk, hypertension, hyperlipidemia, and type 2 diabetes management. The interdisciplinary approach to managing metabolic syndrome was highlighted along with lifestyle modifications and pharmacological agents being evaluated for NASH treatment. Current and promising agents in phase 3 trials targeting lipid metabolism, inflammation, and fibrosis were discussed. The importance of combination therapy due to NASH complexity and ongoing research for new therapeutic options were emphasized. The study on F2 or F3 NASH patients is structured with two parts evaluating NASH resolution, fibrosis improvement, and long-term outcomes over 5 years. The absence of FDA-approved treatments for NASH was noted, underlining the need for proactive screening, lifestyle changes, and proper pharmacological management for NAFLD and NASH patients with comorbidities like type 2 diabetes. The session also covered lifestyle modifications, guidelines for hypertension and hyperlipidemia, and the significance of identifying and treating prediabetes and type 2 diabetes in these patients.

Keywords

Liver Meeting 2020

Hepatology Associates SIG

metabolic syndrome

NAFLD

NASH

diagnosis

treatment

cardiovascular risk

lifestyle modifications

pharmacological agents

NASH treatment